2023年8月15日,
;101 (7)
金博宝手机版官网首页研究文章
长期结果原发性中枢神经系统淋巴瘤R-MVP和大剂量化疗后自体造血干细胞移植
凯特伊丽莎白Therkelsen,视图ORCID概要劳伦·r·Schaff,Subhiksha Nandakumar,安东尼奥议员Omuro,丽萨DeAngelis,基督教Grommes
第一次出版2023年6月21日,
DOI: https://doi.org/10.1212/WNL.0000000000207490
凯特伊丽莎白Therkelsen
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.
劳伦·r·Schaff
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.
Subhiksha Nandakumar
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.
安东尼奥议员Omuro
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.
丽萨DeAngelis
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.
基督教Grommes
的神经病学和神经科学(K.E.T.),斯坦福大首页学医学院的CA;神经病学(L.R.S.首页,L.M.D.,C.G.), Memorial Sloan Kettering Cancer Center; Department of Neurology (L.R.S., L.M.D., C.G.), Weill Cornell Medical College; Human Oncology and Pathogenesis Program (S.N.), Memorial Sloan Kettering Cancer Center, New York; and Department of Neurology (A.M.P.O.), Yale School of Medicine, New Haven, CT.

文章数据和数据
数据
" data-icon-position="" data-hide-link-title="0">

图2
无进展生存率和总体生存率
(A) kaplan meier曲线显示无进展生存(PFS)和总生存期(OS)对所有患者接受了预期的试验治疗(n = 32)。(B) kaplan meier曲线显示PFS和操作系统移植患者(n = 26)。
图3
临床参数HDC-ASCT期间和之后
(A) Karnofsky性能规模(KPS)初次登记试验(初始),完成后高剂量化疗和干细胞拯救(post-ASCT),在最近的后续(当前)显示。(B)神经肿瘤学学会举办的神经系统评估(纳米)得分是基于该标准的标准化评估神经功能域的神经系统检查A8。对每个域规模增加考试/异常的严重程度。NANO的分数在初次登记试验(初始),完成后高剂量化疗和干细胞拯救(post-ASCT),在最近的后续(当前)显示。
图4
脑白质病HDC-ASCT期间和之后
(A) Fluid-attenuated反转恢复(天赋)的MRI代表发达只有最小的脑白质病病人在治疗和长期随访。(B)才能代表更高程度的患者的MRI脑白质病。(C)是显示脑白质病MRI研究参与者的分数才能完成后高剂量化疗和干细胞救援(post-ASCT)和最近的后续(当前)。修改法泽卡斯得分:0:不白质异常;1:轻微的白质病灶;2:开始融合白质病;3:大支流区域;4:融合与大脑皮层和皮层下白质异常的参与;5:弥漫性脑白质病。